Boosting radiation for prostate cancer: a safer cure?

NCT ID NCT03424850

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a higher dose of radiation directly to the prostate (via HDR brachytherapy) can better control early-stage prostate cancer without causing too many side effects. About 36 men with low- or favorable intermediate-risk prostate cancer will receive one of three radiation doses (21, 23, or 25 Gy). Researchers will track PSA levels to measure cancer control and monitor any short- or long-term side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: High dose rate (HDR) brachytherapy (radiation implant)
What this could lead to: If successful, this could establish a more effective radiation dose for early-stage prostate cancer with manageable side effects.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply broadly. Higher radiation doses could increase the risk of urinary or rectal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE NEOPLASM

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.